ID   MV522/MDR1
AC   CVCL_0E37
SY   MV522/mdr1 Q6
DR   ATCC; CRL-2520
DR   cancercelllines; CVCL_0E37
DR   Wikidata; Q54907110
RX   PubMed=9797706;
CC   Problematic cell line: Contaminated. Parent cell line (MV-522) has been shown to be a HT-29 derivative.
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line).
CC   Transfected with: HGNC; 40; ABCB1.
CC   Discontinued: ATCC; CRL-2520; true.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 10
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7204 ! MV-522
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 05-10-23; Version: 20
//
RX   PubMed=9797706; DOI=10.1016/s0959-8049(98)00033-1;
RA   Kelner M.J., McMorris T.C., Estes L.A., Samson K.M., Bagnell R.D.,
RA   Taetle R.;
RT   "Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the
RT   mdr1/gp170 metastatic MV522 lung carcinoma xenograft.";
RL   Eur. J. Cancer 34:908-913(1998).
//